Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
mage-a3 and ny-eso-1 (1 trial)
mage-a3 peptide (1 trial)
Multiple Myeloma (Phase 3)
Neoplasms, Plasma Cell (Phase 3)
Trials (1 total)
Trial APIs (2 total)